Tradestie Institutional Equity Comparison Engine

ZLAB vs HCM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HCM Overall Edge

HCM Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to HUTCHMED (China) Limited American Depositary Shares (HCM) driven by superior Valuation, Growth & Margin while ZLAB counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus HCM at N/M Forward P/E and -6.3% operating margin (+0.2% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against HCM sits in UNCLASSIFIED (73rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HCM
ZLAB N/M vs HCM N/M Fwd P/E
Growth & Margin Winner HCM
Op Margin -63.0% vs -6.3% ยท YoY -6.8% vs +0.2%
Momentum & Technical Winner ZLAB
1Y +9.2% vs -3.9% ยท 52W Pos 60% vs 75%
Options & Structure Winner ZLAB
UNCLASSIFIED (58th %ile IV) vs UNCLASSIFIED (73rd %ile IV)
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.74
-3.5% 1D
Market Cap $3.0B
1M Return +2.37%
1Y Return +9.25%
Forward P/E N/M
Unified AI Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
HCM NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$14.69
-1.44% 1D
Market Cap $2.6B
1M Return +4.52%
1Y Return -3.89%
Forward P/E N/M
Unified AI Score
37.9 / 100 SELL
Tech 8.0 Fund 30.0 Flow 50.0 Mom 36.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZLAB +9.25% HCM -3.89% Spread: +12.51 pp (ZLAB Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ZLAB TTM Op. Margin: -63.0% HCM TTM Op. Margin: -6.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs HCM. Trailing 12-month operating profitability (ZLAB -63.0% vs HCM -6.3%) and valuation multiples (ZLAB N/M vs HCM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZLAB (2) vs HCM (7)
Institutional Metric ZLAB HCM Criterion Row Winner
Market Capitalization Scale $3.0B $2.6B Larger Scale ZLAB
Trailing P/E Ratio Valuation N/M 148.3x Lower Multiple HCM
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -6.8% +0.2% Higher Growth HCM
Operating Margin (TTM) Profitability -63.0% -6.3% Higher Margin HCM
Net Profit Margin Profitability -44.9% 3.3% Higher Margin HCM
Return on Equity (ROE) Capital Efficiency -30.0% 1.5% Higher ROE HCM
52-Week Range Position Momentum 60% ($16โ€“$29) 75% ($10โ€“$16) Stronger Trend HCM
Beta / 30D Volatility Risk Regime 1.19ฮฒ ยท 78% Vol 0.61ฮฒ ยท 45% Vol Lower Realized Risk HCM
Unified Institutional Score Composite Signal 47.4 / 100 (HOLD) 37.9 / 100 (SELL) Higher Composite ZLAB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZLAB vs HCM Buy Guide
ZLAB UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 58th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ZLAB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
HCM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 73rd %ile
IV Regime Elevated (60thโ€“80th %ile)
Live HCM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZLAB nor HCM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.